drugset / Trial / NCT02059616
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.
Timeline
- Start
- 2014-02
- Primary completion
- 2015-06
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 5 mg | Oral |
| Subject | Amlodipine | Other / unclassified | 10 mg | Oral |
| Subject | Candesartan cilexetil | Unknown | 8 mg | Oral |
| Subject | Candesartan cilexetil | Unknown | 16 mg | Oral |